MVA-Based Pandemic Influenza Vaccine Induces Cross-Clade Protection
Author Information
Author(s): Hessel Annett, Schwendinger Michael, Holzer Georg W., Orlinger Klaus K., Coulibaly Sogue, Savidis-Dacho Helga, Zips Marie-Luise, Crowe Brian A., Kreil Thomas R., Ehrlich Hartmut J., Barrett P. Noel, Falkner Falko G.
Primary Institution: Baxter Bioscience, Biomedical Research Center, Orth/Donau, Austria
Hypothesis
The study aims to evaluate the cross-protective potential of hemagglutinins from different H5N1 strains using a modified vaccinia Ankara (MVA) vector vaccine.
Conclusion
The MVA vaccine expressing the hemagglutinin from the VN/1203 strain provided the highest level of cross-protection against various H5N1 clades.
Supporting Evidence
- Mice vaccinated with the VN/1203 hemagglutinin-expressing MVA showed excellent protection against all tested clades.
- The study demonstrated substantial amounts of neutralizing antibodies in vaccinated mice.
- High levels of HA-specific T-cells were induced in vaccinated mice.
- The MVA-HA-VN vaccine provided 100% survival against the homologous VN/1203 strain.
Takeaway
Researchers created a vaccine using a harmless virus to help protect against different types of bird flu, and it worked really well for one specific type.
Methodology
Mice were vaccinated with recombinant MVA viruses expressing hemagglutinin from various H5N1 strains and then challenged with homologous and heterologous strains to assess protection.
Potential Biases
All authors are employees and shareholders of Baxter BioScience, which may influence the study's outcomes.
Limitations
The study used a single dose immunization scheme, which may not reflect the efficacy of a two-dose regimen.
Participant Demographics
Female Balb/c mice, aged 6 to 7 weeks.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website